Anti-inflammatory Approaches in Major Depressive Disorder

Accumulating evidence implicates inflammatory processes in the pathophysiology and treatment resistance of major depressive disorder (MDD). Low-grade systemic inflammation, characterised by elevated levels of pro-inflammatory cytokines and acute-phase proteins, can alter neurotransmitter metabolism, neuroendocrine function and neural plasticity. Anti-inflammatory strategies aim either to modulate peripheral immune mediators or to inhibit central immune activation. Pharmacological interventions include non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase-2 inhibitors, antibiotic-derived immunomodulators and cytokine antagonists. These agents may be administered as adjuncts to standard antidepressant regimens or as standalone therapies in biomarker-stratified subgroups. Mechanistic studies indicate that suppressing microglial activation, restoring tryptophan–kynurenine balance and reshaping the gut–brain axis are key pathways by which inflammation-targeted treatments exert both mood-enhancing and neuroprotective effects. Personalized medicine approaches seek to identify inflammatory signatures predictive of response, thereby optimising therapeutic benefit and minimising adverse outcomes in patients with inflammatory forms of depression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Anti-inflammatory Approaches in Major Depressive Disorder publication trend

The graph below shows the total number of articles in anti-inflammatory approaches in major depressive disorder across all publications each year (not limited to Nature Index journals).

Technical terms

C-reactive protein (CRP): An acute-phase protein produced by the liver in response to inflammation, used as a systemic inflammation biomarker.

Cytokines: Small secreted proteins that regulate immune cell communication and orchestrate inflammatory responses.

Microglia: Resident immune cells of the central nervous system that mediate neuroinflammation and phagocytic clearance.

Cyclooxygenase-2 (COX-2): Enzyme induced in inflammatory states that catalyses the synthesis of pro-inflammatory prostaglandins.

Gut–brain axis: Bidirectional signalling network linking the gastrointestinal tract microbiota, immune system and central nervous system functions.

References

1. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology (2021).
2. Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner. Translational Psychiatry (2019).
3. Inflammation as a treatment target in mood disorders: review. BJPsych Open (2020).